All the news

Sofosbuvir/velpatasvir is safe and effective for the treatment of hepatitis C genotype 4 variants that have naturally occurring resistance to some direct-acting antivirals in the NS5A inhibitor class, a study in Rwanda has ...

The prevalence of hepatitis C in England fell by almost 40% between 2015 and 2020 and deaths due to the virus fell by 35% in the same period, the UK Health Security Agency ...

Curing hepatitis C improves cognitive function, especially in older people already showing signs of cognitive impairment, a Spanish study has found. Cognitive impairment covers a wide spectrum of problems with memory, concentration, learning, attention ...

Curing hepatitis C in people with mild fibrosis by the age of 50 reduces their risk of death to the same level as the rest of the population, Japanese researchers report in ...

Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at the online AASLD Liver Meeting. The study was ...

More than one in ten HIV-positive people in the large EuroSIDA cohort who were cured of hepatitis C were reinfected within two years, according to a report last month at ...

Hepatitis C co-infection does not increase the risk of cardiovascular disease or non-AIDS cancers in people with HIV, an analysis of the large EuroSIDA cohort published in Clinical Infectious Diseases has found. ...

People with hepatitis C who received interferon-based treatment were less likely to develop Parkinson’s disease, a large study from Taiwan has concluded. The results, published in JAMA Neurology, add to the evidence ...

Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ...

Treatment with sofosbuvir/ledipasvir (Harvoni) was well tolerated and cured all pregnant women with hepatitis C virus (HCV), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) ...